Arcturus Therapeutics Holdings (ARCT) Revenue (2018 - 2026)

Arcturus Therapeutics Holdings has reported Revenue for 9 years, with the latest figure at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 92.99% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $54.7 million (down 61.92% YoY), and the FY2025 full-year result was $82.0 million, down 46.14% from the prior year.
• Revenue for Q1 2026 stood at $2.1 million, down from $7.2 million in the prior quarter.
• The five-year high for Revenue was $160.3 million in Q4 2022, with the low at $2.1 million in Q1 2026.
• Historically, Revenue has averaged $35.8 million across 5 years, with a median of $28.3 million in 2025.
• Annual changes were most pronounced in 2022 — Revenue soared 2666.53% — and 2026, when it sank 92.99%.
• Arcturus Therapeutics Holdings' Revenue stood at $160.3 million in 2022, then plunged by 80.75% to $30.9 million in 2023, then dropped by 26.22% to $22.8 million in 2024, then sank by 68.39% to $7.2 million in 2025, then sank by 71.36% to $2.1 million in 2026.
• The last three Revenue figures came in at $2.1 million (Q1 2026), $7.2 million (Q4 2025), and $17.2 million (Q3 2025), per Business Quant data.